Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Prevalence of potential drug–drug interactions in bone marrow transplant patients (2011)

  • Authors:
  • USP affiliated authors: SECOLI, SILVIA REGINA - EE
  • USP Schools: EE
  • DOI: 10.1007/s11096-011-9574-2
  • Subjects: MEDICAMENTO (INTERAÇÃO;PREVALÊNCIA); TRANSPLANTES
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s11096-011-9574-2 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: International Journal of Clinical Pharmacy

    ISSN: 2210-7703

    Citescore - 2017: 1.58

    SJR - 2017: 0.702

    SNIP - 2017: 0.857


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    EE2243573-10SECOLI, S. R. doc 36
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      GUASTALDI, Rosimeire Barbosa Fonseca; REIS, Adriano Max Moreira; FIGUEIRAS, Albert; SECOLI, Silvia Regina. Prevalence of potential drug–drug interactions in bone marrow transplant patients. International Journal of Clinical Pharmacy, The Hague, v. 33, n. 6, p. 1002-1009, 2011. DOI: 10.1007/s11096-011-9574-2.
    • APA

      Guastaldi, R. B. F., Reis, A. M. M., Figueiras, A., & Secoli, S. R. (2011). Prevalence of potential drug–drug interactions in bone marrow transplant patients. International Journal of Clinical Pharmacy, 33( 6), 1002-1009. doi:10.1007/s11096-011-9574-2
    • NLM

      Guastaldi RBF, Reis AMM, Figueiras A, Secoli SR. Prevalence of potential drug–drug interactions in bone marrow transplant patients. International Journal of Clinical Pharmacy. 2011 ; 33( 6): 1002-1009.
    • Vancouver

      Guastaldi RBF, Reis AMM, Figueiras A, Secoli SR. Prevalence of potential drug–drug interactions in bone marrow transplant patients. International Journal of Clinical Pharmacy. 2011 ; 33( 6): 1002-1009.

    Referências citadas na obra
    Fuhr U. Improvement in the handling of drug–drug interactions. Eur J Clin Pharmacol. 2008;64:167–71.
    Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546–58.
    Van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011. (ahead of print). doi: 10.1093/annonc/mdq761 .
    Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.
    Mihara A, Mori T, Aisa Y, Yamazaki R, Iketani O, Tanigawara Y, Ikeda Y, Okamoto S. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol. 2008;64:89–91.
    Secoli SR, Figueras A, Lebrão ML, Lima FD, Santos JL. Risk of potential drug–drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging. 2010;27:759–70.
    Nagamura F, Takahashi T, Takeuchi M, Iseki T, Ooi J, Tomonari A, Uchimaru K, Takahashi S, Tojo A, Tani K, Asano S. Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:1051–8.
    Egger SS, Meier S, Leu C, Christen S, Gratwohl A, Krähenbühl S, Haschke M. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant. 2010;45:1197–203.
    Klasco RK editor. Drug Reax® System. Thomson Micromedex, Greenwood Village, Colorado, USA. Available on: http://www.periodicos.capes.gov.br Accessed 28 June 2008.
    Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30(4):367–374. doi: 10.1007/s11096-008-9191-x .
    Reis AMM, Cassiani SHB. Evaluation of three brands of drug interaction software for use in intensive care units. Pharm World Sci. 2010;32(6):822–828. doi: 10.1007/s11096-010-9445-2 .
    World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2011. Available from URL: http://www.whocc.no/atcddd/index . Accessed 04 Aug 2011.
    Riechelmann RP, Zimmermann C, Chin SN, Wang L, O’Carroll A, Zarinehbaf S, Krzyzanowska MK. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symp Manag. 2008;35:535–43.
    Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant. 2004;33:137–52.
    Freeman DL, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporine—phenytoin interaction with observations on cyclosporine metabolites. Br J Clin Pharmacol. 1984;18(6):887–93.
    Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation. 1984;38(3):304–6.
    Ng TM, Bell AM, Hong C, Hara JM, Touchette DR, Danskey KN, Lindsay TT, Puumala SE. Pharmacists monitoring of QTc interval—prolonging medications in critically ill medical patients: a pilot study. Ann Pharmacother. 2008;42:475–82.
    Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug related QT interval prolongation. Pharmacotherapy. 2003;23:881–908.
    Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K. Fluconazol and levofloxacin—induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm. 2003;60:2479–83.
    Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.
    Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. Frequency of potential azole drug–drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf. 2005;14:755–67.
    Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother. 1993;27:427–30.
    Egger SS, Drewe J, Shlienger RG. Potential drug–drug interactions in the mediation of medical patient at hospital discharge. Eur J Clin Pharmacol. 2003;58:773–8.
    Delafuente JC. Understanding and preventing drug–drug interactions in elderly patients. Critic Rev Oncol Hematol. 2003;48:133–43.
    Zwart-van Rijkom J, Uijtendaal E, Ten Berg M, Van Solinge W, Egberts A. Frequency and nature of drug–drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2010;68(2):187–93.
    Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, Tuccori M, Conforti A. Identifying adverse drug reactions associated with drug–drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667–75.
    Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. 2006;61(6):515–20.
    Vonbach P, Dubied A, Krähenbühl S, Beer JH. Recognition and management of potential drug–drug interactions in patient on internal medicine wards. Eur J Clin Pharmacol. 2007;63:1075–83.